Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Shanghai Jiao Tong University

Status: Completed

Conditions: Infant, Premature, Diseases

Treatments: Drug: intravitreal ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT03115255

XH-17-004

Details and patient eligibility

About

To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab

Full description

Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked immunosorbent assay, and the changes of the serum VEGF levels are determined.

Enrollment: 17 patients

Sex: All

Ages: 4 weeks to 3 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infants with vascularly active ROP
• intravitreal ranibizumab

Exclusion criteria

• already accepted laser therapy

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

serum VEGF level

Experimental group

Description:

Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab

Treatment:

Drug: intravitreal ranibizumab